Senesco Technologies, Inc. (AMEX:SNT) has completed an additional sale of approximately 485,000 units at $2.37 per unit, comprised of one share of newly issued common stock and a warrant to purchase 0.50 of a share of common stock at an exercise price of $3.79 per share to an institutional investor. Aggregate proceeds to the Company were approximately $1.15 million. In connection with this sale, the Company issued an additional warrant to purchase 0.15 of a share of common stock for each share of common stock previously purchased by the investors in the private placement. Pursuant to the terms of the private placement, such investors had received a warrant to purchase 0.35 of a share of common stock for each share of common stock purchased.

Bruce Galton, Senesco's President and CEO commented, "This closing completes our private placement. We believe that this financing, together with the $2.5 million financing we previously announced, provides sufficient funds for our planned operating and research activities through the end of calendar year 2005."

The proceeds of the financing are expected to be used for general corporate purposes, including working capital and capital expenditures, and for research and development.

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States in the absence of an effective registration statement or exemption from registration requirements.

In connection with the private placement, Senesco has agreed to file a registration statement on Form S-3 by March 18, 2004 to register the shares of common stock and the shares of common stock underlying the warrants.

Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has begun to explore ways to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as Alzheimer's, glaucoma, ischemia and arthritis, among others. Senesco partners with leading-edge companies and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, New Jersey, and utilizes research laboratories at the University of Waterloo in Ontario, Canada and the University of Colorado in Denver, Colorado.